title: Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer.
abstract: OBJECTIVE
  To explore the incidence of subclinical cardiotoxicity in women treated with adjuvant trastuzumab in the early breast cancer setting using cardiac magnetic resonance imaging (cMRI).
  
  
  METHODS
  The cardiac function and myocardial tissue characteristics of 25 women who had completed adjuvant trastuzumab therapy greater than 6 months previously was evaluated using MRI and comparing this with symptoms and routine echocardiography.
  
  
  RESULTS
  Evidence of myocardial tissue damage was seen in two women in the absence of functional change or previous cardiac symptoms.
  
  
  CONCLUSIONS
  Tissue characterization using cMRI may provide a useful tool in defining trastuzumab induced cardiotoxicity.
authors.affiliation: St Vincent's Hospital Clinical School, University of New South Wales, Sydney, New South Wales, Australia. claire.lawley@student.unsw.edu.au
authors.forename: Claire
authors.initials: C
authors.lastname: Lawley
authors.forename: Camilla
authors.initials: C
authors.lastname: Wainwright
authors.forename: Eva
authors.initials: E
authors.lastname: Segelov
authors.forename: Jodi
authors.initials: J
authors.lastname: Lynch
authors.forename: Jane
authors.initials: J
authors.lastname: Beith
authors.forename: Jane
authors.initials: J
authors.lastname: McCrohon
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000175:diagnosis*; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D010865:Pilot Projects; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab